Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin in Healthy Adult Participants
Conditions
Interventions
GSK3640254
Placebo
+1 more
Locations
1
United States
GSK Investigational Site
Austin, Texas, United States
Start Date
November 9, 2020
Primary Completion Date
October 30, 2021
Completion Date
October 30, 2021
Last Updated
December 6, 2023
NCT04142047
NCT06694805
NCT07428330
NCT05398185
NCT07225530
NCT07429864
Lead Sponsor
ViiV Healthcare
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions